Cid:[email protected] (6d85f252 307c 4aa8 9572 1e74c9819283 00)
Drospirenone And Ethinyl Estradiol Kit
Product Images NDC 50090-2494
10 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Drospirenone And Ethinyl Estradiol (NDC 50090-2494). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Cid:[email protected] (6d85f252 307c 4aa8 9572 1e74c9819283 01)
Figure1 (Figure1)
A forest plot comparing various studies by their hazard ratios, rate ratios, or odds ratios, each represented by a diamond marker with horizontal error bars. Studies are grouped as Prospective Cohort Studies, Retrospective Cohort Studies, Case-Control Studies, and Non-fatal idiopathic cases only. The horizontal axis uses a logarithmic scale ranging from 0.1 to 10, with a vertical reference line at 1, indicating relative risk or association metrics.*
Figure2 (Figure2)
A horizontal bar chart titled 'Likelihood of Developing a VTE' comparing the number of women with a blood clot per 10,000 woman-years across four categories: Non-Pregnant Non-COC user, COC-User, Pregnancy, and Postpartum (12 weeks only). Bars indicate ranges from 1 to 5, 3 to 9, 5 to 20, and 40 to 65 respectively, highlighting increased risk levels. An explanatory note addresses the pregnancy data assumption.*
Drospirenone Structure (Image 03)
Chemical structure of drospirenone, a synthetic steroidal compound used as an active ingredient in hormonal contraceptives.*
Ethinyl Estradiol Structure (Image 04)
Chemical structure diagram of the active ingredient ethinyl estradiol, showing its molecular framework with hydroxyl groups and characteristic rings.*
Img1 (Img1)
An infographic illustrating pregnancy rates per 100 women in one year relative to different birth control methods. It ranks effectiveness from fewer pregnancies (top) to more pregnancies (bottom), listing implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring, condoms, diaphragm, abstinence during fertile days, spermicide, withdrawal, and no birth control.*
Img2 (Img2)
Illustration of a drospirenone and ethinyl estradiol tablet kit showing a hand holding the edge of a blister pack labeled with days of the week to organize daily dosage. The kit includes tablets arranged in four weekly rows, with the strength indicated as 3 mg/0.03 mg on the packaging.*
Img3 (Img3)
A horizontal bar chart showing the number of women with a blood clot per 10,000 women years (WY) across four groups: Non-Pregnant Non-COC users (1-5 cases), COC users (3-9 cases), Pregnant women (5-20 cases), and Postpartum women (12 weeks only) with the highest range of 40-65 cases. The chart includes a note explaining pregnancy data assumptions related to duration and risk rates.*
Label Image (Lbl500902494)
Packaging label for drospirenone and ethinyl estradiol 3 mg/0.03 mg kit from A-S Medication Solutions. The label instructs storing at 70 degrees Fahrenheit and indicates the kit contains 1 blister of 28 tablets with color specifications. Includes dosage packaging insert information and the product number 6688-0.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
